Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ESS310 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ESS310 | EXPERIMENTAL | All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure. |
| Name | Type | Description |
|---|---|---|
| ESS310 (BAY1454032) | DEVICE | - |
Inclusion Criteria: * Females aged range 21 to 44 years * Subjects seeking permanent contraception * Subjects with body weight within range of 90-300 pounds (40 - 136 kilograms) * Subjects for whom medical history indicates bilateral viable and patent fallopian tubes * Subjects are able and willing...
ESS310 is an investigational device being studied for contraception. It was evaluated in a Phase 3 clinical trial in the United States. The study, NCT02064413, was a placement rate study for the Essure Model ESS310, and it has been completed.
ESS310 is developed by Bayer AG, which trades under the ticker BAYRY. The company conducted a Phase 3 clinical trial for this contraceptive device in the United States.
ESS310 is in Phase 3 clinical development. A Phase 3 trial, NCT02064413, has been completed. This trial was an uncontrolled study that enrolled 134 female participants aged 21 years and older.
ESS310 has one completed clinical trial, NCT02064413, titled "Essure (Model ESS310) Placement Rate Study." This Phase 3 study was conducted in the United States and enrolled 134 healthy female volunteers for contraception.
ESS310 is a model of the Essure device. The clinical trial NCT02064413 is titled "Essure (Model ESS310) Placement Rate Study," indicating that ESS310 is a specific version of the Essure contraceptive system.